|
|
|
|
| 通心络胶囊治疗急性卒中 |
|
|
|
|
|
| Tongxinluo capsule for acute stroke |
|
|
|
|
|
| Zhuo Q., Yang X., Wu T., Liu G., Zhou L. 2009/5/29 18:39:20 |
|
|
【发表评论】
|
|
|
|
|
打印|
推荐给好友
|
|
|
Cochrane Database of Systematic Reviews, 2008, Volume 0, Issue 4
|
|
|
|
|
|
|
| Background: Tongxinluo capsules are a compound of Chinese traditional medicine which contain substances that are thought to have vasodilatory, antiplatelet, anticoagulant, thrombolytic and even lipid-lowering properties, and therefore may improve outcome after acute ischaemic stroke. To date the evidence of its effect has not been systematically reviewed, making it difficult to derive robust conclusions about its actual benefits, and indeed, possible harms. Objectives: To assess the effectiveness and possible harms of tongxinluo capsule for acute cerebral infarction compared with control. Search strategy: We searched the Cochrane Stroke Group trials register (last searched on 24 January 2008) the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, Issue 4, 2007), MEDLINE (1995 to 2006), EMBASE (1995 to 2006), China National Knowledge Infrastructure (CNKI, 1994 to 2006), CBM (Chinese Biomedical Database) (1995 to 2006), Current Controlled Trials (www.controlled-trials.com), National Research Register (http://www.update- software.com/national/). We handsearched 30 journals (1995 to 2006), and contacted drug companies and the principal of included trials. Selection criteria: Randomised controlled trials comparing tongxinluo with placebo or open control (or tongxinluo plus standard therapy versus standard therapy alone) in people with definite acute stroke. We excluded trials if they sought to recruit patients with transient ischaemic attacks (TIA), intracerebral haemorrhage, heart failure, or renal failure. Data collection and analysis: Two review authors extracted data and assessed trial quality. Main results: Only two poor quality studies with a total of 232 participants were included in this review. Neither study reported any of our pre-specified outcomes, so no reliable estimate of the effect of treatment on major clinical outcomes could be obtained. Authors' conclusions: It was not possible to reliably determine whether tongxinluo has a favourable or unfavourable effect in acute ischaemic stroke. High quality trials are required to assess the efficacy and safety of tongxinluo capsule for acute ischaemic stroke. Copyright © 2008 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. |
|
|
|
|
|
|
| Correspondence Address: Wu, T.; Chinese Cochrane Centre, West China Hospital, Sichuan University, No. 37, Guo Xue Xiang, Chengdu, Sichuan, 610041, China; email: txwutx@hotmail.com |
|
|
|
|
|
|
|
|
|
|
|
请登录后发表评论，点击此处登录。
|
|
|
 疾病资源中心
王燕燕 王曙
上海交通大学附属瑞金医院内分泌科
患者，女，69岁。2009年1月无明显诱因下出现乏力，当时程度较轻，未予以重视。2009年3月患者乏力症状加重，尿色逐渐加深，大便习惯改变，颜色变淡。4月18日入我院感染科治疗，诉轻度头晕、心慌，体重减轻10kg。无肝区疼痛，无发热，无腹痛、腹泻、腹胀、里急后重，无恶性、呕吐等。入院半月前于外院就诊，查肝功能：ALT 601IU/L，AST 785IU/L，TBIL 97.7umol/L，白蛋白 41g/L，甲状腺功能：游离T3 30.6pmol/L，游离T4 51.9pmol/L，心电图示快速房颤。
医学数据库
|
